Studying the Safety and Effectiveness of an Investigation

Build status - In Progress

Recruiting

18 years - 80 years

All

24 participants needed

1 Location

Brief description of study

The purpose of Part A of this study is to evaluate the safety, tolerability, and cardiac pharmacodynamics (the effect of the study drug on your heart) of the study drug, danicamtiv, when administered by mouth twice a day for approximately one to two weeks. Part A which may last between 4 and 11 weeks, and an optional Part B which may last up to about 104 weeks.

Detailed description of study

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Heart, Dilated Cardiomyopathy
Age: 18 years - 80 years
Gender: All

Ages 18 to 80 Diagnosed with Dilated Cardiomyopathy (DCM) due to a mutation in either MYH7 or TTN, both of which are genes involved in the function of heart muscle.

Updated on 04 Aug 2024. Study ID: 848993

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.